摘要
目的:评估晚期非小细胞肺癌(non-small cell lungcancer,NSCLC)患者癌症相关性乏力的发生情况及其与化疗之间的相互关系。方法:应用疲乏数字等级量表评估本院2009年1月—2009年12月120例晚期NSCLC患者的乏力指数。所有患者均完成4个疗程含铂双药联合化疗及为期1年的随访。化疗前、每2个疗程化疗后以及随访期间评估乏力指数。结果:120例晚期NSCLC患者中,轻度乏力29例(24.2%),中度乏力64例(53.3%),重度乏力27例(22.5%)。化疗期间,平均乏力指数呈进行性升高,4个疗程化疗结束时达最高值5.31;随访期间,乏力指数呈下降趋势,随访6个月时平均乏力指数降至最低值3.95。美国东部肿瘤协作组体能状况评分与乏力相关(P<0.01),而年龄、性别、病理学类型和临床分期均与乏力指数无相关性。疾病稳定(4.26±2.27和3.64±1.75)与部分缓解(4.27±2.28和2.33±1.50)患者在随访3个月时的乏力指数较化疗前下降,疾病进展患者随访3个月时的乏力指数较化疗前升高(4.48±2.09和5.00±1.75),差异均有统计学意义(P<0.01)。结论:癌症相关性乏力在晚期NSCLC患者中的发生率较高,化疗可加重乏力程度。体能状况和化疗疗效与乏力指数相关。
Objective： To examine the incidence of cancer-related fatigue in patients with advanced non- small cell lung cancer （NSCLC） and explore the relationship between chemotherapy and cancer-related fatigue. Methods： One hundred and twenty patients with advanced NSCLC were enrolled between January 2009 and December 2009. All patients received four cycles of platinum-based doublet chemotherapy, and then they were followed-up for one year. The fatigue score was evaluated before chemotherapy, every 2 cycles during the period of chemotherapy and every three months during the follow-up by using fatigue numerical rating scale. Results： In 120 patients with advanced NSCLC, 29 （24.2%） patients had mild fatigue, 64 （53.3%） patients had moderate fatigue, and 27 （22.5%） patients had severe fatigue. The average cancer- related fatigue score was increased progressively during chemotherapy and reached the highest value of 5.31 after 4 cycles of chemotherapy, and then it tended to decline and touch the lowest value of 3.95 after six- month follow-up. The Eastern Cooperative Oncology Group performance status （ECOG PS） score is the only one factor related to cancer-related fatigue （P〈0.01）, and the age, gender, pathology and clinical stage were not associated with cancer-related fatigue. The fatigue score was decreased in patients with stable disease （4.26±2.27 vs 3.64±1.75, P〈0.01） or partial response （4.27±2.28 vs 2.33±1.50, P〈0.01） after three- month follow-up as compared with that before chemotherapy, whereas the fatigue score was increased in patients with progressive disease （4.48±2.09 vs 5.00±1.75, P〈0.01）. Conclusion： The cancer-related fatigue occurred in advanced NSCLC with a very high incidence, and the chemotherapy can strengthen the intensity of cancer-related fatigue, which is related to ECOG PS score and response to chemotherapy.
出处
《肿瘤》
CAS
CSCD
北大核心
2011年第12期1108-1110,共3页
Tumor
关键词
癌
非小细胞肺
癌症相关性乏力
抗肿瘤联合化疗方案
Carcinoma, non-small cell lung
Cancer-related fatigue
Antineoplastic combined chemotherapy protocols
